YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Core Insights - YD Bio Limited has successfully listed on the Nasdaq Global Market, enhancing its capital base and global profile while accelerating the commercialization of its diagnostic and regenerative medicine platforms [1][2] Company Overview - YD Bio Limited is a biotechnology company focused on advancing clinical trials, drug development, cancer prevention diagnostics, and therapies using stem cells and exosomes [3] - The company aims to improve patient outcomes through scientific innovation and precision medicine, and has expanded into the development and distribution of post-market auxiliary products [3] Strategic Partnerships - YD Bio has secured exclusive 20-year licenses from EG Biomed and 3D Global Biotech, which positions the company to scale its non-invasive cfDNA methylation tests for early cancer detection and exosome-based eye therapies globally [2] - The strategic alliances with EG BioMed Co., Ltd. and 3D Global Biotech Inc. provide a significant competitive advantage and support a promising pipeline targeting multi-billion-dollar markets [2]